Last updated: February 17, 2026
What Is the Market and Regulatory Status of TYLENOL W/ CODEINE NO. 1?
TYLENOL W/ CODEINE NO. 1 is a combination analgesic consisting of acetaminophen and codeine. It is classified as a Schedule III controlled substance in the United States, indicating moderate abuse potential with accepted medical use. Its primary markets are the U.S., Canada, and select countries with regulated opioid markets.
In the U.S., it is available via prescription, with regulatory oversight provided by the Food and Drug Administration (FDA). The drug has faced shifts in regulatory stance due to rising concerns over opioid misuse, leading to tighter control and scrutiny. Its recent regulatory history includes a 2018 FDA advisory recommending increased warnings and potential reclassification discussions.
Globally, usage is subject to varying opioid regulations, impacting market size potential. Countries with strict opioid control, like Australia and some European nations, limit access or avoid approval of combination products containing codeine.
How Are the Sales Trends and Market Potential?
In the U.S., prescription volume peaked in the late 2000s but declined by approximately 20% from 2010 to 2020, paralleling the reduction in opioid prescriptions nationwide. The CDC reported a 15% decline in overall opioid prescriptions from 2012 to 2019. The decline reflects increased regulatory restrictions and public health campaigns addressing opioid misuse.
Market estimates:
| Year |
U.S. Prescription Volume (millions) |
Global Market (est., millions of units) |
| 2015 |
12.5 |
20 |
| 2018 |
10.2 |
17 |
| 2020 |
9.8 |
15 |
The global market remains limited, constrained by regulatory barriers, with annual sales estimated at $400 million in the U.S. and a combined global value of approximately $600–800 million. The U.S. accounts for roughly 70–75% of the market.
The decline reflects increased preference for alternative, non-opioid analgesics and abuse-deterrent formulations. The overall market for combination opioids is projected to contract further at a CAGR of around 3% over the next five years unless new formulations or indications emerge.
What Are the Key Patent and Regulatory Challenges?
Patent protection on TYLENOL W/ CODEINE NO. 1 typically expired around the early 2000s, leading to generic competition. As an off-patent product, exclusive rights are scarce, reducing potential revenue streams from brand protection.
Regulatory challenges include potential reclassification or scheduling changes. The FDA has moved toward stricter control over opioid products, including risk evaluation and mitigation strategies (REMS). Any tightening could restrict prescribing or limit formulations, affecting revenue.
Legal risks involve potential liability related to opioid misuse and adverse events. Lawsuits have increased, and manufacturers face significant financial exposure.
What Is the R&D and Pipeline Outlook?
Limited R&D activity exists for TYLENOL W/ CODEINE NO. 1 specifically, given patent expiration and declining market demand. Companies focus R&D on:
- Abuse-deterrent formulations,
- Non-opioid analgesic alternatives,
- Combination therapies with lower abuse potential.
Certain companies are developing formulations incorporating abuse-deterrent technology or novel delivery systems. These efforts may help align with regulatory requirements but have marginal impact on the existing product.
What Are the Investment Implications?
Investments in the commercially available product face headwinds:
- Declining prescription volumes
- Regulatory restrictions
- Patent expirations leading to price erosion
Potential value lies in reformulation opportunities or pipeline products that address opioid misuse concerns. Companies with active R&D programs targeting abuse-resistant formulations may see growth prospects if regulatory approval is achieved.
For companies relying solely on generic sales, revenue growth prospects are limited. Licensing opportunities for abuse-deterrent technologies are of more interest, especially if they can be integrated into newer formulations.
Key Takeaways
- TYLENOL W/ CODEINE NO. 1 has a shrinking market due to declining prescriptions and regulatory pressures.
- The product faces patent expiration and generic competition, limiting upside.
- Regulatory landscape is tightening, with potential reclassification risks affecting future sales.
- Investment risk remains high for current formulations; value shifts toward development of abuse-deterrent or non-opioid alternatives.
- Companies with innovative formulations may sustain or grow market share if they navigate regulatory hurdles effectively.
Frequently Asked Questions
1. Is TYLENOL W/ CODEINE NO. 1 still profitable?
Profitability has decreased due to declining prescriptions, price erosion from generics, and regulatory restrictions.
2. Are there opportunities for reformulation?
Yes, abuse-deterrent formulations and non-opioid alternatives are actively under development, offering growth potential.
3. How does regulatory risk impact investments?
Increased regulation and potential reclassification threaten sales and can elevate compliance costs or reduce prescribing.
4. What are the competitive advantages for companies developing new formulations?
Possessing proprietary abuse-deterrent technologies and regulatory approvals can create barriers to entry for competitors.
5. Is the global market sustainable?
Global markets are constrained by strict regulation; growth depends on regulatory relaxations and successful product innovations.
Sources:
[1] FDA Office of Drug Evaluation and Research, 2022
[2] CDC Prescription Opioid Data, 2021
[3] IQVIA Prescription Trends, 2020
[4] European Medicines Agency Regulatory Updates, 2022
